CHRDL1 and neoplasm: Another integrated mRNA–lncRNA signature was developed based on the mRNA species for FCGR1A, RSAD2, CHRDL1, and the lncRNA species for HIF1A-AS2 and AK124454, which may be applied to predict tumor recurrence and the benefit of taxane chemotherapy in TNBC (33).